The hypocretin system and psychiatric disorders

Current Psychiatry Reports

Volumn 16, Issue 2, 2014, Pages

  Pizza, Fabio ^a,b   Magnani, Michele ^a   Indrio, Camilla ^a   Plazzi, Giuseppe ^a,b,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Abuse; Addiction; Anxiety disorders; Dopamine; Eating disorders; Feeding; Hallucinations; Hypocretin; Hypothalamus; Major depression; Mood disorders; Narcolepsy with cataplexy; Orexin; Reward; Schizophrenia; Sleep

Indexed keywords

ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; NEUROPEPTIDE;

HUMAN; MENTAL DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; MENTAL DISORDERS; NEUROPEPTIDES;

EID: 84890340160     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0433-9     Document Type: Article

References (112)

1. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92: 573-85. (Pubitemid 28101119)
2. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95: 322-7. (Pubitemid 28103952)
3. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98: 365-76. (Pubitemid 29380571)
4. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98: 437-51. (Pubitemid 29402482)
5. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6: 991-7.
6. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27: 469-74.
7. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355: 39-40. (Pubitemid 30072183)
8. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol. 2001;50: 381-8. (Pubitemid 32848741)
9. American Academy of Sleep Medicine. ICSD-2- International classification of sleep disorders: Diagnostic and coding manual. 2nd ed. Westchester-Illinois; 2005.
10. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437: 1257-63. (Pubitemid 41568665)
11. Sakurai T, Nagata R, Yamanaka A, Kawamura H, Tsujino N, Muraki Y, et al. Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron. 2005;46: 297-308. (Pubitemid 40545784)
12. Yoshida K, McCormack S, España RA, Crocker A, Scammell TE. Afferents to the orexin neurons of the rat brain. J Comp Neurol. 2006;494: 845-61. (Pubitemid 43054230)
13. Yamuy J, Fung SJ, Xi M, Chase MH. Hypocretinergic control of spinal cord motoneurons. J Neurosci. 2004;24: 5336-45. (Pubitemid 38747675)
14. Plazzi G, Moghadam KK, Maggi LS, Donadio V, Vetrugno R, Liguori R, et al. Autonomic disturbances in narcolepsy. SleepMed Rev. 2011;15: 187-96.
15. Tsujino N, Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci. 2013;7:28.
16. Gelineau JBE. De la Narcolepsy (I).Gaz desHôp. 1880;54: 626-8.
17. Gelineau JBE. De la Narcolepsy (II). Gaz des Hôp. 1880;54: 635-7.
18. Westphal C. Eigentümliche mit Einschlafen verbundene Anfälle. Arch f Psych 1877: 631-5.
19. Löwenfeld L. Über Narkolepsie Münch Med Wochenschr. 1902;49: 1041-5.
20. Lhermitte J. Les narcolepsies. Rev de Psychiat et de Psychol expér. 1910;14:265.
21. Wilson KS. The Narcolepsies. Brain. 1928;51: 63-109.
22. Adie W. Idiopathic narcolepsy: a disease sui generis; with remarks on the mechanism of sleep. Brain. 1926;49: 257-306.
23. Von Economo C. Sleep as a problem of localization. J Nerv Ment Disease. 1930;71: 249-59.
24. Vogel G. Studies in psychophysiology of dreams. III The dreamof narcolepsy Arch Gen Psychiatry. 1960;3: 421-8.
25. Yoss RE, Daly DD. Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo. 1957;32: 320-8.
26. Matsuki K, Grumet FC, Lin X, Gelb M, Guilleminault C, Dement WC, et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet. 1992;339:1052.
27. Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmayer J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep. 1994;17(8 Suppl):S60-7.
28. Kornum BR, Faraco J, Mignot E. Narcolepsy with hypocretin/ orexin deficiency, infections and autoimmunity of the brain. Curr Opin Neurobiol. 2011;21: 897-903.
29. Fortuyn HA, Lappenschaar MA, Furer JW, Hodiamont PP, Rijnders CA, Renier WO, et al. Anxiety and mood disorders in narcolepsy: a case-control study. Gen Hosp Psychiatry. 2010;32: 49-56.
30. Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14: 488-92.
31. Vignatelli L, Plazzi G, Peschechera F, Delaj L, D'Alessandro R. A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. Sleep Med. 2011;12: 19-23.
32. Kishi Y, Konishi S, Koizumi S, Kudo Y, Kurosawa H, Kathol RG. Schizophrenia and narcolepsy: a review with a case report. Psychiatry Clin Neurosci. 2004;58: 117-24. (Pubitemid 38470531)
33. Talih FR. Narcolepsy presenting as schizophrenia: a literature review and two case reports. Innov Clin Neurosi. 2011;8: 30-4.
34. Vourdas A, Shneerson JM, Gregory CA, Smith IE, King MA, Morrish E, et al. Narcolepsy and psychopathology: is there an association? Sleep Med. 2002;3: 353-60.
35. Walterfang M, Upjohn E, Velakoulis D. Is schizophrenia associated with narcolepsy? Cogn Behav Neurol. 2005;18: 113-8. (Pubitemid 40946424)
36. Chien WT, Yip AL. Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments. Neuropsychiatr Dis Treat. 2013;9: 1311-32.
37. Howes OD, Fusar-Poli P, Bloomfield M, Selvaraj S, McGuire P. From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des. 2012;18: 459-65.
38. van Os J. Kapur S Schizophrenia Lancet. 2009;374: 635-45.
39. Catts VS, Fung SJ, Long LE, Joshi D, Vercammen A, Allen KM, et al. Shannon Weickert C. Rethinking schizophrenia in the context of normal neurodevelopment Front Cell Neurosci. 2013;7:60.
40. Yoon JH, Minzenberg MJ, Raouf S, D'Esposito M, Carter CS. Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol Psychiatry. 2013;74: 122-9.
41. Lindenmayer JP, Nasrallah H, Pucci M, James S, Citrome L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res. 2013;147: 241-52.
42. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148: 1474-86.
43. Fortuyn HA, Lappenschaar GA, Nienhuis FJ, Furer JW, Hodiamont PP, Rijnders CA, et al. Psychotic symptoms in narcolepsy: phenomenology and a comparisonwith schizophrenia.Gen Hosp Psychiatry. 2009;31: 146-54.
44. Douglass AB, Shipley JE, Haines RF, Scholten RC, Dudley E, Tapp A. Schizophrenia, narcolepsy, and HLA-DR15, DQ6. Biol Psychiatry. 1993;34: 773-80. (Pubitemid 23362904)
45. Szucs A, Janszky J, Holló A, Migléczi G, Halász P. Misleading hallucinations in unrecognized narcolepsy. Acta Psychiatr Scand 2003;108:314-6; dicussion 316-7. (Pubitemid 37175908)
46. Kondziella D, Arlien-Soborg P. Diagnostic and therapeutic challenges in narcolepsy-related psychosis. J Clin Psychiatry. 2006;67: 1817-9. (Pubitemid 44955166)
47. Melamed Y, Daliahu Y, Paleacu D. Narcolepsy and psychotic states - A case report. Isr J Psychiatry Relat Sci. 2009;46: 70-3.
48. Dahmen N, Kasten M, Mittag K, Müller MJ. Narcoleptic and schizophrenic hallucinations. Implications for differential diagnosis and pathophysiology Eur J Health Econ. 2002;3 Suppl 2:S94-8. (Pubitemid 36389009)
49. Nishino S, Ripley B, Mignot E, Benson KL, Zarcone VP. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 2002;110: 1-7. (Pubitemid 34451091)
50. Dalal MA, Schuld A, Pollmächer T. Lower CSF hypocretin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects. Mol Psychiatry. 2003;8: 836-7.
51. Fadel J, Bubser M, Deutch AY. Differential activation of hypocretin neurons by antipsychotic drugs associated with weight gain. J Neurosci. 2002;22: 6742-6. (Pubitemid 35386430)
52. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382: 951-62.
53. Deutch AY, Bubser M. The hypocretins/hypocretins and schizophrenia. Schizophr Bull. 2007;33: 1277-83.
54. Scoriels L, Jones PB, Sahakian BJ.Modafinil effects on cognition and emotion in schizophrenia and its neurochemicalmodulation in the brain. Neuropharmacology. 2013;64: 168-84.
55. Morein-Zamir S, Turner DC, Sahakian BJ. A review of the effects of modafinil on cognition in schizophrenia. Schizophr Bull. 2007;33: 1298-306. (Pubitemid 350022777)
56. Borgland SL, Labouèbe G. Hypocretin/hypocretin in psychiatric disorders: present state of knowledge and future potential. Neuropsychopharmacology. 2010;35:353-4.
57. Calipari ES, España RA. Hypocretin/hypocretin regulation of dopamine signaling: implications for reward and reinforcement mechanisms. Front Behav Neurosci. 2012;6:54.
58. Murray GK. The emerging biology of delusions. Psychol Med. 2011;41: 7-13.
59. LaCrosse AL, Olive MF. Neuropeptide systems and schizophrenia. CNS Neurol Disord Drug Targets. 2013;12: 619-32.
60. Lambe EK, Aghajanian GK. Hypocretin (hypocretin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice. Neuron. 2003;40: 139-50. (Pubitemid 37222469)
61. Lambe EK, Liu RJ, Aghajanian GK. Schizophrenia, hypocretin (hypocretin), and the thalamocortical activating system. Schizophr Bull. 2007;33: 1284-90. (Pubitemid 350022776)
62. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. TR. Washington DC; 1994.
63. Brundin L, Petersén A, BjörkqvistM, Träskman-Bendz L. Orexin and psychiatric symptoms in suicide attempters. J Affect Disord. 2007;100: 259-63. (Pubitemid 46818444)
64. Brundin L, Björkqvist M, Petersén A, Träskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol. 2007;17: 573-9. (Pubitemid 47068932)
65. Schmidt FM, BrügelM, Kratzsch J, Strauss M, Sander C, Baum P, et al. Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls. Neurosci Lett. 2010;483: 20-2.
66. Schmidt FM, Arendt E, Steinmetzer A, Bruegel M, Kratzsch J, Strauss M, et al. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res. 2011;190:240-3.
67. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry. 2003;54: 96-104. (Pubitemid 36859768)
68. Rainero I, Ostacoli L, Rubino E, Gallone S, Picci LR, Fenoglio P, et al. Association between major mood disorders and the hypocretin receptor 1 gene. J Affect Disord. 2011;130: 487-91.
69. Rotter A, Asemann R, Decker A, Kornhuber J, Biermann T. Orexin expression and promoter-methylation in peripheral blood of patients suffering from major depressive disorder. J Affect Disord. 2011;131: 186-92.
70. Schoenknecht P, Olbrich S, Sander C, Spindler P, Hegerl U. Treatment of acute mania with modafinil monotherapy. Biol Psychiatry. 2010;67: 55-7.
71. Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M, et al. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety. 2011;28: 297-302.
72. Wichniak A, Wierzbicka A, Jernajczyk W. Sleep as a biomarker for depression. Int Rev Psychiatry. 2013;25: 632-45.
73. Allard JS, Tizabi Y, Shaffery JP, Trouth CO, Manaye K. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides. 2004;38: 311-5. (Pubitemid 39298731)
74. Allard JS, Tizabi Y, Shaffery JP, Manaye K. Effects of rapid eye movement sleep deprivation on hypocretin neurons in the hypothalamus of a rat model of depression. Neuropeptides. 2007;41: 329-37. (Pubitemid 47247862)
75. Ito N, Yabe T, Gamo Y, Nagai T, Oikawa T, Yamada H, et al. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience. 2008;157: 720-32.
76. Gérard A, Liard F, Crochard A, Goni S, Millet B. Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment. Neuropsychiatr Dis Treat. 2012;8: 605-14.
77. Craske MG, Rauch SL, Ursano R, Prenoveau J, Pine DS, Zinbarg RE.What is an anxiety disorder?Depress Anxiety. 2009;26: 1066-85.
78. Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am JMed Genet C: Semin Med Genet. 2008;148: 89-98. (Pubitemid 351705126)
79. Hoehn-Saric R, McLeod DR. Anxiety and arousal: physiological changes and their perception. J Affect Disord. 2000;6: 217-24. (Pubitemid 32119268)
80. Johnson PL, Truitt WA, Fitz SD, Lowry CA, Shekhar A. Neural pathways underlying lactate-induced panic. Neuropsychopharmacology. 2008;33: 2093-107. (Pubitemid 351992091)
81. Johnson PL, Molosh A, Fitz SD, Truitt WA, Shekhar A. Orexin, stress, and anxiety/panic states. Prog Brain Res. 2012;198:133-61.
82. Kayaba Y, Nakamura A, Kasuya Y, Ohuchi T, Yanagisawa M, Komuro I, et al. Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol. 2003;285: 581-93.
83. Suzuki M, Beuckmann CT, Shikata K, Ogura H, Sawai T. Orexin- A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Brain Res. 2005;1044: 116-21. (Pubitemid 40616058)
84. Rodgers RJ, Wright FL, Snow NF, Taylor LJ. Orexin-1 receptor antagonism fails to reduce anxiety-like behaviour in either plusmaze- naïve or plus-maze-experienced mice. Behav Brain Res. 2013;243: 213-9.
85. Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S, et al. A key role for orexin in panic anxiety. Nat Med. 2010;16: 111-5.
86. Johnson PL, Samuels BC, Fitz SD, Federici LM, Hammes N, Early MC, et al. Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network. Physiol Behav. 2012;107: 733-42.
87. Strawn JR, Pyne-Geithman GJ, Ekhator NN, Horn PS, Uhde TW, Shutter LA, et al. Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder. Psychoneuroendocrinology. 2010;35: 1001-7.
88. Annerbrink K, Westberg L, Olsson M, Andersch S, Sjödin I, Holm G, et al. Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene. Psychiatr Genet. 2011;21: 85-9.
89. Girault EM, Yi CX, Fliers E, Kalsbeek A. Orexins, feeding, and energy balance. Prog Brain Res. 2012;198: 47-64.
90. Cason AM, Smith RJ, Tahsili-Fahadan P, Moorman DE, Sartor GC, Aston-Jones G. Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Physiol Behav. 2010;100: 419-28.
91. Bronsky J, Nedvidkova J, Krasnicanova H, Vesela M, Schmidtova J, Koutek J, et al. Changes of orexin A plasma levels in girls with anorexia nervosa during eight weeks of realimentation. Int J Eat Disord. 2011;44: 547-52.
92. Janas-Kozik M, Stachowicz M, Krupka-Matuszczyk I, Szymszal J, Krysta K, Janas A, et al. Plasma levels of leptin and orexin A in the restrictive type of anorexia nervosa. Regul Pept. 2011;168: 5-9.
93. Caraci F, Drago F. New definition of addiction proposed by the American Society of Addiction Medicine: Which implications for the treatment of tobacco dependence? Eur Neuropsychopharmacol 2013. doi:pii:S0924-977X(13)00147-8.
94. Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res. 2012;198:79-121.
95. Martin-Fardon R, Boutrel B. Orexin/hypocretin (Orx/Hcrt) transmission and drug-seeking behavior: is the paraventricular nucleus of the thalamus (PVT) part of the drug seeking circuitry? Front Behav Neurosci. 2012;6:75.
96. Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol. 2007;7: 69-76. (Pubitemid 46238042)
97. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35: 217-38.
98. Feltenstein MW, See RE. The neurocircuitry of addiction: an overview. Br J Pharmacol. 2008;154: 261-74. (Pubitemid 351670601)
99. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron. 2006;49: 589-601. (Pubitemid 43221893)
100. España RA, Oleson EB, Locke JL, Brookshire BR, Roberts DC, Jones SR. The hypocretin-orexin system regulates cocaine selfadministration via actions on the mesolimbic dopamine system. Eur J Neurosci. 2010;31: 336-48.
101. España RA, Melchior JR, Roberts DC, Jones SR. Hypocretin 1/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration. Psychopharmacology. 2011;214: 415-26.
102. Quarta D, Valerio E, Hutcheson DM, Hedou G, Heidbreder C. The orexin-1 receptor antagonist SB-334867 reduces amphetamineevoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization. Neurochem Int. 2010;56: 11-5.
103. Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, et al. Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. Brain Res. 2010;1314: 74-90.
104. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci. 2003;23: 3106-11. (Pubitemid 36531950)
105. Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, Miyatake M, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci. 2006;26: 398-405. (Pubitemid 43237102)
106. Schneider ER, Rada P, Darby RD, Leibowitz SF, Hoebel BG. Orexigenic peptides and alcohol intake: differential effects of orexin, galanin, and ghrelin. Alcohol Clin Exp Res. 2007;31: 1858-65. (Pubitemid 47609647)
107. Jupp B, Krivdic B, Krstew E, Lawrence AJ. The orexin-1 receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. Brain Res. 2011;1391: 54-9.
108. Jupp B, Krstew E, Dezsi G, Lawrence AJ. Discrete cueconditioned alcohol-seeking after protracted abstinence: pattern of neural activation and involvement of orexin-1 receptors. Br J Pharmacol. 2011;162: 880-9.
109. Bayerlein K, Kraus T, Leinonen I, Pilniok D, Rotter A, Hofner B, et al. Orexin A expression and promoter methylation in patients with alcohol dependence comparing acute and protracted withdrawal. Alcohol. 2011;45: 541-7.
110. von der Goltz C, Koopmann A, Dinter C, Richter A, Grosshans M, Fink T, et al. Involvement of orexin in the regulation of stress, depression and reward in alcohol dependence. Horm Behav. 2011;60: 644-50.
111. Zhou Y, Cui CL, Schlussman SD, Choi JC, Ho A, Han JS, et al. Effects of cocaine place conditioning, chronic escalating-dose "binge" pattern cocaine administration and acute withdrawal on orexin/hypocretin and preprodynorphin gene expressions in lateral hypothalamus of Fischer and Sprague-Dawley rats. Neuroscience. 2008;153: 1225-34.
112. Boutrel B, Steiner N, Halfon O. The hypocretins and the reward function: what have we learned so far? Front Behav Neurosci. 2013;7:59.